Home » Stocks » TBPH

Theravance Biopharma, Inc. (TBPH)

Stock Price: $17.49 USD -0.16 (-0.91%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $17.78 +0.29 (1.66%) Feb 24, 7:30 PM
Market Cap 1.12B
Revenue (ttm) 82.63M
Net Income (ttm) -285.19M
Shares Out 63.30M
EPS (ttm) -4.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $17.49
Previous Close $17.65
Change ($) -0.16
Change (%) -0.91%
Day's Open 19.14
Day's Range 17.13 - 19.14
Day's Volume 1,108,145
52-Week Range 14.48 - 31.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 14 hours ago

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

Benzinga - 1 day ago

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.37% over the past year to ($0...

PRNewsWire - 2 weeks ago

DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization o...

PRNewsWire - 2 weeks ago

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of...

PRNewsWire - 1 month ago

DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization o...

Zacks Investment Research - 2 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 2 months ago

Today, we revisit Theravance Biopharma for the first time in over a year. The stock has had a challenging year in 2020, but there are some potentially significant catalysts on the horizon in 2...

Zacks Investment Research - 3 months ago

Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.

Seeking Alpha - 3 months ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.37% and 3.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

PRNewsWire - 3 months ago

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September...

PRNewsWire - 4 months ago

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization o...

Zacks Investment Research - 5 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 5 months ago

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, JAZZ, TXAC, TXG
PRNewsWire - 5 months ago

DUBLIN, Sept. 1, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

Seeking Alpha - 6 months ago

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

Zacks Investment Research - 6 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

Zacks Investment Research - 6 months ago

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization o...

PRNewsWire - 7 months ago

DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the disco...

Zacks Investment Research - 7 months ago

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

PRNewsWire - 7 months ago

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical compa...

Zacks Investment Research - 8 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Seeking Alpha - 9 months ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 11 months ago

Theravance Biopharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump T...

Zacks Investment Research - 11 months ago

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.41% and 60.93%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Investors didn't like the drugmaker's pricing of a planned public stock offering.

Zacks Investment Research - 1 year ago

Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

The Motley Fool - 1 year ago

Despite achieving several milestones over the past two years, the stock’s response has been muted.

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 1 year ago

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

Other stocks mentioned: ABBV, BIIB, INVA, MYL, NVS, REGN
Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2019 - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0.00% and -6.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Neil Woodford, the unlucky British fund manager who was yesterday ousted from his flagship fund, is (was) Theravance's largest shareholder.

Zacks Investment Research - 1 year ago

Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.

Seeking Alpha - 1 year ago

Theravance Biopharma has had a 'stealth' 20% rally over the last month despite the recent spike in market volatility.

Zacks Investment Research - 1 year ago

Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.

Seeking Alpha - 1 year ago

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2019 Results - Earnings Call Transcript

About TBPH

Theravance Biopharma, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal dis... [Read more...]

Industry
Biotechnology
CEO
Rick Winningham
Employees
316
Stock Exchange
NASDAQ
Ticker Symbol
TBPH
Full Company Profile

Financial Performance

In 2019, TBPH's revenue was $73.41 million, an increase of 21.61% compared to the previous year's $60.37 million. Losses were -$236.46 million, 9.71% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is 31.22, which is an increase of 78.50% from the latest price.

Price Target
$31.22
(78.50% upside)
Analyst Consensus: Buy